Phibro Animal Health (PAHC) 10-Q 8 May 24 2024 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - $ / shares	9 Months Ended
	Mar. 31, 2024	May 03, 2024
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2024
Entity File Number	001-36410
Entity Registrant Name	Phibro Animal Health Corporation
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	13-1840497
Entity Address, Address Line One	Glenpointe Centre East, 3rd Floor
Entity Address, Address Line Two	300 Frank W. Burr Boulevard
Entity Address, Address Line Three	Suite 21
Entity Address, City or Town	Teaneck
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07666-6712
City Area Code	201
Local Phone Number	329-7300
Title of 12(b) Security	Class A Common Stock, $0.0001 par value per share
Trading Symbol	PAHC
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Interactive Data Current	Yes
Entity Emerging Growth Company	false
Entity Shell Company	false
Current Fiscal Year End Date	--06-30
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3
Entity Central Index Key	0001069899
Amendment Flag	false
Common Class A [Member]
Document Information [Line Items]
Entity Listing, Par Value Per Share	$ 0.0001
Entity Common Stock, Shares Outstanding		20,337,574
Common Class B [Member]
Document Information [Line Items]
Entity Listing, Par Value Per Share	$ 0.0001
Entity Common Stock, Shares Outstanding		20,166,034

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Net sales	$ 263,223	$ 245,673	$ 744,515	$ 722,840
Cost of goods sold	183,623	170,133	518,573	501,269
Gross profit	79,600	75,540	225,942	221,571
Selling, general and administrative expenses	59,676	56,987	191,043	173,490
Operating income	19,924	18,553	34,899	48,081
Interest expense, net	4,575	3,871	13,798	10,822
Foreign currency losses (gains), net	2,427	(422)	16,593	4,629
Income before income taxes	12,922	15,104	4,508	32,630
Provision for income taxes	4,517	5,062	2,844	11,522
Net income	$ 8,405	$ 10,042	$ 1,664	$ 21,108
Net income per share
basic (in dollars per share)	$ 0.21	$ 0.25	$ 0.04	$ 0.52
diluted (in dollars per share)	$ 0.21	$ 0.25	$ 0.04	$ 0.52
Weighted average common shares outstanding
basic (in shares)	40,504	40,504	40,504	40,504
diluted (in shares)	40,520	40,504	40,509	40,504

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
Net Income (Loss)	$ 8,405	$ 10,042	$ 1,664	$ 21,108
Change in fair value of derivative instruments	(1,793)	(3,765)	(8,407)	1,804
Foreign currency translation adjustment	(3,045)	1,469	(2,187)	1,597
Pension settlement recognition			10,674
Unrecognized net pension gains	92	177	837	545
(Provision) benefit for income taxes	357	896	(711)	(587)
Other comprehensive income (loss)	(4,389)	(1,223)	206	3,359
Comprehensive income	$ 4,016	$ 8,819	$ 1,870	$ 24,467

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Jun. 30, 2023
ASSETS
Cash and cash equivalents	$ 50,225	$ 41,281
Short-term investments	48,523	40,000
Accounts receivable, net	161,087	163,479
Inventories, net	282,289	277,570
Other current assets	55,056	63,393
Total current assets	597,180	585,723
Property, plant and equipment, net	202,061	195,568
Intangibles, net	48,239	54,987
Goodwill	54,644	53,274
Other assets	76,911	81,845
Total assets	979,035	971,397
LIABILITIES AND STOCKHOLDERS' EQUITY
Current portion of long-term debt and other	29,811	22,295
Accounts payable	82,613	73,853
Accrued expenses and other current liabilities	76,648	79,852
Total current liabilities	189,072	176,000
Revolving credit facility	165,000	141,000
Long-term debt	291,008	311,541
Other liabilities	63,861	60,347
Total liabilities	708,941	688,888
Commitments and contingencies (Note 8)
Common stock, par value $0.0001 per share; 300,000,000 Class A shares authorized, 20,337,574 shares issued and outstanding at March 31, 2024, and June 30, 2023; 30,000,000 Class B shares authorized, 20,166,034 shares issued and outstanding at March 31, 2024, and June 30, 2023	4	4
Preferred stock, par value $0.0001 per share; 16,000,000 shares authorized, no shares issued and outstanding
Paid-in capital	136,099	135,803
Retained earnings	247,995	260,912
Accumulated other comprehensive loss	(114,004)	(114,210)
Total stockholders' equity	270,094	282,509
Total liabilities and stockholders' equity	$ 979,035	$ 971,397

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parentheticals) - $ / shares	Mar. 31, 2024	Jun. 30, 2023
Preferred stock
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	16,000,000	16,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common Class A
Common stock
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	300,000,000	300,000,000
Common stock, shares issued (in shares)	20,337,574	20,337,574
Common stock, shares outstanding (in shares)	20,337,574	20,337,574
Common Class B
Common stock
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	30,000,000	30,000,000
Common stock, shares issued (in shares)	20,166,034	20,166,034
Common stock, shares outstanding (in shares)	20,166,034	20,166,034

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
OPERATING ACTIVITIES
Net income	$ 1,664	$ 21,108
Adjustments to reconcile net income to net cash provided (used) by operating activities:
Depreciation and amortization	26,977	25,438
Amortization of debt issuance costs	780	514
Deferred income taxes	(6,806)	235
Foreign currency losses (gains), net	4,261	(5,024)
Acquisition-related items	1,033
Pension settlement cost	10,674
Brazil employment taxes	4,202
Stock-based compensation	296
Other	3,865	(1,201)
Changes in operating assets and liabilities, net of business acquisition:
Accounts receivable, net	3,045	14,985
Inventories, net	(5,891)	(30,458)
Other current assets	3,437	(7,481)
Other assets	624	(317)
Accounts payable	8,099	(19,718)
Accrued expenses and other liabilities	2,905	(5,009)
Net cash provided (used) by operating activities	59,165	(6,928)
INVESTING ACTIVITIES
Purchases of short-term investments	(65,523)	(40,000)
Maturities of short-term investments	57,000	17,000
Capital expenditures	(28,166)	(40,903)
Business acquisition, net of cash acquired	(3,282)
Other, net	888	167
Net cash used by investing activities	(39,083)	(63,736)
FINANCING ACTIVITIES
Revolving credit facility borrowings	155,000	229,000
Revolving credit facility repayments	(131,000)	(181,000)
Proceeds from long-term debt		12,000
Payments of long-term debt	(15,315)	(11,460)
Debt issuance costs		(640)
Proceeds from insurance premium financing and other short-term debt	2,694
Payments of insurance premium financing and other short-term debt	(5,353)
Dividends paid	(14,581)	(14,581)
Net cash (used) provided by financing activities	(8,555)	33,319
Effect of exchange rate changes on cash	(2,583)	335
Net increase (decrease) in cash and cash equivalents	8,944	(37,010)
Cash and cash equivalents at beginning of period	41,281	74,248
Cash and cash equivalents at end of period	$ 50,225	$ 37,238

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Common Stock	Paid-in Capital	Retained Earnings (Accumulated Deficit)	Accumulated Other Comprehensive Income (Loss)	Total
Balance at Jun. 30, 2022	$ 4	$ 135,803	$ 247,748	$ (121,113)	$ 262,442
Balance (in shares) at Jun. 30, 2022	40,503,608
Increase (Decrease) in Stockholders' Equity
Comprehensive (loss) income			3,856	1,318	5,174
Dividends declared			(4,860)		(4,860)
Balance at Sep. 30, 2022	$ 4	135,803	246,744	(119,795)	262,756
Balance (in shares) at Sep. 30, 2022	40,503,608
Balance at Jun. 30, 2022	$ 4	135,803	247,748	(121,113)	262,442
Balance (in shares) at Jun. 30, 2022	40,503,608
Increase (Decrease) in Stockholders' Equity
Comprehensive (loss) income					24,467
Balance at Mar. 31, 2023	$ 4	135,803	254,275	(117,754)	272,328
Balance (in shares) at Mar. 31, 2023	40,503,608
Balance at Sep. 30, 2022	$ 4	135,803	246,744	(119,795)	262,756
Balance (in shares) at Sep. 30, 2022	40,503,608
Increase (Decrease) in Stockholders' Equity
Comprehensive (loss) income			7,210	3,264	10,474
Dividends declared			(4,860)		(4,860)
Balance at Dec. 31, 2022	$ 4	135,803	249,094	(116,531)	268,370
Balance (in shares) at Dec. 31, 2022	40,503,608
Increase (Decrease) in Stockholders' Equity
Comprehensive (loss) income			10,042	(1,223)	8,819
Dividends declared			(4,861)		(4,861)
Stock-based compensation expense		135			135
Balance at Mar. 31, 2023	$ 4	135,803	254,275	(117,754)	272,328
Balance (in shares) at Mar. 31, 2023	40,503,608
Balance at Jun. 30, 2023	$ 4	135,803	260,912	(114,210)	282,509
Balance (in shares) at Jun. 30, 2023	40,503,608
Increase (Decrease) in Stockholders' Equity
Comprehensive (loss) income			(8,015)	3,354	(4,661)
Dividends declared			(4,860)		(4,860)
Stock-based compensation expense		81			81
Balance at Sep. 30, 2023	$ 4	135,884	248,037	(110,856)	273,069
Balance (in shares) at Sep. 30, 2023	40,503,608
Balance at Jun. 30, 2023	$ 4	135,803	260,912	(114,210)	282,509
Balance (in shares) at Jun. 30, 2023	40,503,608
Increase (Decrease) in Stockholders' Equity
Comprehensive (loss) income					1,870
Balance at Mar. 31, 2024	$ 4	136,099	247,995	(114,004)	270,094
Balance (in shares) at Mar. 31, 2024	40,503,608
Balance at Sep. 30, 2023	$ 4	135,884	248,037	(110,856)	273,069
Balance (in shares) at Sep. 30, 2023	40,503,608
Increase (Decrease) in Stockholders' Equity
Comprehensive (loss) income			1,274	1,241	2,515
Dividends declared			(4,861)		(4,861)
Stock-based compensation expense		80			80
Balance at Dec. 31, 2023	$ 4	135,964	244,450	(109,615)	270,803
Balance (in shares) at Dec. 31, 2023	40,503,608
Increase (Decrease) in Stockholders' Equity
Comprehensive (loss) income			8,405	(4,389)	4,016
Dividends declared			(4,860)		(4,860)
Balance at Mar. 31, 2024	$ 4	$ 136,099	$ 247,995	$ (114,004)	$ 270,094
Balance (in shares) at Mar. 31, 2024	40,503,608

CONSOLIDATED STATEMENTS OF CH_2

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parentheticals) - $ / shares	3 Months Ended
	Mar. 31, 2024	Dec. 31, 2023	Sep. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022
Dividends declared
Dividends declared (in dollars per share)	$ 0.12	$ 0.12	$ 0.12	$ 0.12	$ 0.12	$ 0.12

Description of Business

Description of Business	9 Months Ended
	Mar. 31, 2024
Description of Business
Description of Business	1. Description of Business Phibro Animal Health Corporation (“Phibro” or “PAHC”) and its subsidiaries (together, the “Company”) is a diversified global developer, manufacturer and marketer of a broad range of animal health and mineral nutrition products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture and dogs. The Company is also a manufacturer and marketer of performance products for use in the personal care, industrial chemical and chemical catalyst industries. Unless otherwise indicated or the context requires otherwise, references in this report to “we,” “our,” “us,” and similar expressions refer to Phibro and its subsidiaries. The unaudited consolidated financial information for the three and nine months ended March 31, 2024 and 2023, is presented on the same basis as the financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2023 (the “Annual Report”), filed with the Securities and Exchange Commission on August 30, 2023 (File no. 001-36410). In the opinion of management, these financial statements include all adjustments necessary for a fair statement of the financial position, results of operations and cash flows of the Company for the interim periods, and the adjustments are of a normal and recurring nature. The financial results for any interim period are not necessarily indicative of the results for the full year. The consolidated balance sheet information as of June 30, 2023, was derived from the audited consolidated financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States of America (“GAAP”). The unaudited consolidated financial information should be read in conjunction with the consolidated financial statements and notes thereto included in the Annual Report. The consolidated financial statements include the accounts of Phibro and its consolidated subsidiaries. Intercompany balances and transactions have been eliminated from the consolidated financial statements. The decision to consolidate an entity requires consideration of majority voting interests, as well as effective control over the entity. ​

Summary of Significant Accounti

Summary of Significant Accounting Policies and New Accounting Standards	9 Months Ended
	Mar. 31, 2024
Summary of Significant Accounting Policies and New Accounting Standards
Summary of Significant Accounting Policies and New Accounting Standards	2. Summary of Significant Accounting Policies and New Accounting Standards Our significant accounting policies are described in the notes to the consolidated financial statements included in our Annual Report. As of March 31, 2024, there have been no material changes to any of the significant accounting policies contained therein. Net Income per Share and Weighted Average Shares Basic net income per share is calculated by dividing net income by the weighted average number of common shares outstanding during the reporting period. Diluted net income per share is calculated by dividing net income by the weighted average number of common shares outstanding during the reporting period after giving effect to dilutive common share equivalents, resulting from the assumed vesting of restricted stock units, unless the effect would be antidilutive. Common share equivalents were included in the calculation of diluted net income per share for the three and nine months ended March 31, 2024. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months ​ Nine Months ​ For the Periods Ended March 31 2024 2023 2024 2023 Net income ​ $ 8,405 ​ $ 10,042 ​ $ 1,664 ​ $ 21,108 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average number of shares – basic ​ 40,504 ​ 40,504 ​ 40,504 ​ 40,504 ​ Dilutive effect of restricted stock units ​ ​ 16 ​ ​ — ​ ​ 5 ​ ​ — ​ Weighted average number of shares - diluted ​ ​ 40,520 ​ ​ 40,504 ​ ​ 40,509 ​ ​ 40,504 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net income per share ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ basic ​ $ 0.21 ​ $ 0.25 ​ $ 0.04 ​ $ 0.52 ​ diluted ​ $ 0.21 ​ $ 0.25 ​ $ 0.04 ​ $ 0.52 ​ ​ New Accounting Standards Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, ​ ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures,

Statements of Operations-Additi

Statements of Operations-Additional Information	9 Months Ended
	Mar. 31, 2024
Statements of Operations-Additional Information
Disaggregated Revenue, Deferred Revenue and Customer Payment Terms	Disaggregated revenue, deferred revenue and customer payment terms We develop, manufacture and market a broad range of products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. The products help prevent, control and treat diseases and enhance nutrition to help improve animal health and well-being. We sell animal health and mineral nutrition products directly to integrated poultry, cattle and swine customers and through commercial animal feed manufacturers, distributors and veterinarians. The animal health industry and demand for many of the animal health products in a particular region are affected by changing disease pressures and by weather conditions, as product usage follows varying weather patterns and seasons. Our operations are primarily focused on regions where the majority of livestock production is consolidated in large commercial farms. We have a diversified portfolio of products that are classified within our three business segments—Animal Health, Mineral Nutrition and Performance Products. Each segment has its own dedicated management and sales team. Animal Health The Animal Health business develops, manufactures and markets products in three main categories: ● MFAs and other: MFAs and other products primarily consist of concentrated medicated products administered through animal feeds, commonly referred to as Medicated Feed Additives (“MFAs”). Specific product classifications include antibacterials, which inhibit the growth of pathogenic bacteria that cause bacterial infections in animals; anticoccidials, which inhibit the growth of coccidia (parasites) that damage the intestinal tract of animals; and other related products. The MFAs and other category also includes antibacterials and other processing aids used in the ethanol fermentation industry. ● Nutritional specialties: Nutritional specialty products enhance nutrition to help improve health and performance in areas such as immune system function and digestive health. We are also a developer, manufacturer and marketer of microbial products and bioproducts for a variety of applications serving animal health and nutrition, environmental, industrial and agricultural customers. ● Vaccines: Vaccine products are primarily focused on preventing diseases in poultry, swine, beef and dairy cattle and aquaculture. They protect animals from either viral or bacterial disease challenges. We develop, manufacture and market conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. We have developed and market an innovative and proprietary delivery platform for vaccines. Mineral Nutrition The Mineral Nutrition business is comprised of formulations and concentrations of trace minerals such as zinc, manganese, copper, iron and other compounds, with a focus on customers in North America. Our customers use these products to fortify the daily feed requirements of their livestock’s diets and maintain an optimal balance of trace elements in each animal. We manufacture and market a broad range of mineral nutrition products for food animals including poultry, swine, and beef and dairy cattle. Performance Products The Performance Products business manufactures and markets specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries. The following tables present our revenues disaggregated by major product category and geographic region: Net Sales by Product Type ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months ​ Nine Months For the Periods Ended March 31 2024 2023 2024 2023 Animal Health ​ ​ ​ ​ ​ MFAs and other ​ $ 108,216 ​ $ 93,217 ​ $ 304,261 ​ $ 283,186 Nutritional specialties ​ 40,194 ​ 45,016 ​ 121,840 ​ 127,926 Vaccines ​ 32,923 ​ 26,201 ​ 88,866 ​ 71,984 Total Animal Health ​ $ 181,333 ​ $ 164,434 ​ $ 514,967 ​ $ 483,096 Mineral Nutrition ​ 64,228 ​ 62,922 ​ 181,601 ​ 184,212 Performance Products ​ 17,662 ​ 18,317 ​ 47,947 ​ 55,532 Total ​ $ 263,223 ​ $ 245,673 ​ $ 744,515 ​ $ 722,840 ​ Net Sales by Region ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months ​ Nine Months For the Periods Ended March 31 2024 2023 2024 2023 United States ​ $ 159,314 ​ $ 148,529 ​ $ 431,083 ​ $ 433,716 Latin America and Canada ​ 53,653 ​ 53,881 ​ 177,539 ​ 159,946 Europe, Middle East and Africa ​ 33,175 ​ 28,174 ​ 89,572 ​ 85,518 Asia Pacific ​ 17,081 ​ 15,089 ​ 46,321 ​ 43,660 Total ​ $ 263,223 ​ $ 245,673 ​ $ 744,515 ​ $ 722,840 ​ Net sales by region are based on country of destination. Our customer payment terms generally range from 30 to 120 days globally and do not include any significant financing components. Payment terms vary based on industry and business practices within the regions in which we operate. Our average worldwide collection period for accounts receivable is approximately 60 days after the revenue is recognized.
Additional Information	Interest Expense, Net ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months ​ Nine Months ​ For the Periods Ended March 31 2024 2023 2024 2023 ​ Interest expense, net ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2021 Credit Facilities ​ $ 5,127 ​ $ 4,517 ​ $ 15,421 ​ $ 12,316 ​ 2022 Term Loan ​ ​ 215 ​ ​ 191 ​ ​ 648 ​ ​ 379 ​ Amortization of debt issuance costs ​ 260 ​ 188 ​ 780 ​ 514 ​ Other ​ 43 ​ 10 ​ 164 ​ 20 ​ Interest expense ​ 5,645 ​ 4,906 ​ 17,013 ​ 13,229 ​ Interest income ​ (1,070) ​ (1,035) ​ (3,215) ​ (2,407) ​ ​ ​ $ 4,575 ​ $ 3,871 ​ $ 13,798 ​ $ 10,822 ​ ​ Depreciation and Amortization ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months ​ Nine Months For the Periods Ended March 31 2024 2023 2024 2023 Depreciation and amortization ​ ​ ​ ​ ​ ​ Depreciation of property, plant and equipment ​ $ 6,770 ​ $ 6,067 ​ $ 19,638 ​ $ 18,177 Amortization of intangible assets ​ 2,426 ​ 2,422 ​ 7,339 ​ 7,261 ​ ​ $ 9,196 ​ $ 8,489 ​ $ 26,977 ​ $ 25,438 ​ Pension Settlement ​

Balance Sheets-Additional Infor

Balance Sheets-Additional Information	9 Months Ended
	Mar. 31, 2024
Balance Sheets-Additional Information
Balance Sheets-Additional Information	4. Balance Sheets—Additional Information ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ June 30, As of 2024 2023 Inventories ​ ​ ​ ​ ​ Raw materials ​ $ 75,638 ​ $ 84,328 Work-in-process ​ ​ 26,110 ​ ​ 22,350 Finished goods ​ ​ 180,541 ​ ​ 170,892 ​ ​ $ 282,289 ​ $ 277,570 ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ June 30, As of 2024 2023 Other assets ​ ​ ​ ​ ​ ​ ROU operating lease assets ​ $ 37,100 $ 35,759 Deferred income taxes ​ 14,506 ​ 8,711 Deposits ​ 2,338 ​ 6,617 Insurance investments ​ 6,171 ​ 6,067 Equity method investments ​ 5,081 ​ 5,027 Derivative instruments ​ ​ 2,733 ​ ​ 10,225 Debt issuance costs ​ 1,035 ​ 1,408 Other ​ ​ 7,947 ​ ​ 8,031 ​ ​ $ 76,911 $ 81,845 ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, June 30, As of 2024 2023 Accrued expenses and other current liabilities ​ ​ Employee related ​ $ 30,908 ​ $ 29,359 Current operating lease liabilities ​ 7,107 ​ 6,053 Commissions and rebates ​ ​ 5,953 ​ ​ 5,833 Professional fees ​ 7,581 ​ 5,032 Income and other taxes ​ ​ 5,294 ​ ​ 8,663 Insurance-related ​ 1,397 ​ 1,284 Insurance premium financing ​ ​ 661 ​ ​ 4,769 Other ​ 17,747 ​ 18,859 ​ ​ $ 76,648 ​ $ 79,852 ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, June 30, As of 2024 2023 Other liabilities ​ ​ ​ ​ ​ ​ Long-term operating lease liabilities ​ $ 30,062 ​ $ 29,077 Long-term and deferred income taxes ​ 15,106 ​ ​ 12,146 Supplemental retirement benefits, deferred compensation and other ​ ​ 6,768 ​ ​ 6,552 U.S. pension plan, net ​ 1,644 ​ 2,286 International retirement plans ​ 3,282 ​ 4,210 Other long-term liabilities ​ 6,999 ​ 6,076 ​ ​ $ 63,861 ​ $ 60,347 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, June 30, As of 2024 2023 Accumulated other comprehensive loss ​ ​ ​ ​ Derivative instruments ​ $ 16,182 ​ $ 24,589 Foreign currency translation adjustment ​ (117,249) ​ (115,062) Unrecognized net pension losses ​ (12,485) ​ (23,996) Income tax (provision) benefit ​ (452) ​ 259 ​ ​ $ (114,004) ​ $ (114,210)

Debt

Debt	9 Months Ended
	Mar. 31, 2024
Debt
Debt	5. Debt Term Loans and Revolving Credit Facilities In April 2021, we entered into an amended and restated credit agreement (the “2021 Credit Agreement”) under which we had a term A loan in an aggregate initial principal amount of $300,000 (the “2021 Term A Loan”) and a revolving credit facility under which we could borrow up to an aggregate amount of $250,000, subject to the terms of the 2021 Credit Agreement (the “2021 Revolver”). In November 2022, we amended the 2021 Credit Facilities to increase the revolving commitments under the 2021 Revolver to an aggregate amount of $310,000 and to adopt Secured Overnight Financing Rate (“SOFR”) as the reference for the fluctuating rate of interest on the 2021 Credit Facilities, replacing the London Interbank Offered Rate (“LIBOR”) reference rate. In June 2023, we obtained an additional incremental term loan (the “2023 Incremental Term Loan”) in the amount of $50,000 (the 2021 Revolver, the 2021 Term A Loan and the 2023 Incremental Term Loan are collectively referred to as the “2021 Credit Facilities”). The 2021 Term A Loan and the 2023 Incremental Term Loan are repayable in quarterly installments, with the balances payable at maturity. The 2021 Revolver contains a letter of credit facility. The interest rate per annum applicable to the 2021 Revolver and the 2021 Term A Loan is based on a fluctuating rate of interest plus an applicable rate equal to 1.50%, 1.75%, 2.00% or 2.25%, in the case of adjusted SOFR rate loans and 0.50%, 0.75%, 1.00% or 1.25%, in the case of base rate loans. The interest rate per annum applicable to the 2023 Incremental Term Loan is based on a fluctuating rate of interest plus an applicable rate equal to 2.00%, 2.25%, 2.50% or 2.75%, in the case of adjusted SOFR rate loans and 1.00%, 1.25%, 1.50% or 1.75%, in the case of base rate loans. The applicable rates are based on the First Lien Net Leverage Ratio (as defined in the 2021 Credit Agreement). The 2021 Credit Facilities mature in April 2026 The 2021 Credit Agreement requires, among other things, compliance with financial covenants that permit: (i) a maximum First Lien Net Leverage Ratio of 4.00:1.00 (or, specifically with respect to the test periods ended March 31, 2024, and ending June 30, 2024, a maximum of 4.25:1.00); and (ii) a minimum interest coverage ratio of 3.00:1.00, each calculated on a trailing four-quarter basis. The 2021 Credit Agreement contains an acceleration clause should an event of default (as defined in the 2021 Credit Agreement) occur. As of March 31, 2024, we were in compliance with the financial covenants. As of March 31, 2024, we had $165,000 in borrowings drawn under the 2021 Revolver and had outstanding letters of credit of $2,294, leaving $142,706 available for further borrowings and letters of credit under the 2021 Revolver, subject to restrictions in our 2021 Credit Facilities. We obtain letters of credit in connection with certain regulatory and insurance obligations, inventory purchases and other contractual obligations. The terms of these letters of credit are all less than one year. Other Long-Term Debt ​ In September 2022, we entered into a credit agreement (the “2022 Term Loan”) in the amount of $12,000, collateralized by certain facilities. The 2022 Term Loan matures in September 2027. The interest rate per annum applicable to the 2022 Term Loan is based on a fluctuating rate of interest, at the Company’s election from time to time, equal to either (i) one-month adjusted SOFR plus 2.00%, or (ii) a base rate determined by reference to the greater of (a) the prime rate and (b) the Federal Funds Effective Rate plus 0.50%. The 2022 Term Loan is repayable in monthly installments of $35, with the balance payable at maturity. ​ Interest Rates Interest rates as of the balance sheet dates and the weighted-average rates for the periods presented were: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine Months ​ ​ March 31, June 30, ​ Ended March 31 ​ ​ 2024 2023 ​ 2024 ​ 2023 ​ 2021 Revolver 6.09 % 6.09 % 6.17 % 5.07 % 2021 Term A Loan ​ 2.36 % 2.36 % ​ 2.36 % 2.37 % 2023 Incremental Term Loan ​ 7.69 % 7.44 % ​ 7.63 % — ​ 2022 Term Loan ​ 7.43 % 7.25 % ​ 7.41 % 6.07 % ​ Interest rates as of the balance sheet dates are based on rates in effect as of those dates, including SOFR fluctuating rates of interest, applicable rates and the interest rate swap agreement. We are a party to an interest rate swap agreement on $300,000 of notional principal that effectively converts the floating SOFR portion of our interest obligation on that amount of debt to a fixed rate of 0.61% through June 2025 Debt Maturities ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ June 30, As of ​ 2024 ​ 2023 2021 Term A Loan due April 2026 ​ $ 262,500 ​ $ 273,750 2023 Incremental Term Loan due April 2026 ​ ​ 46,250 ​ ​ 50,000 2022 Term Loan due September 2027 ​ ​ 11,370 ​ ​ 11,685 Other ​ 1,891 ​ — ​ ​ 322,011 ​ 335,435 Unamortized debt issuance costs ​ (1,192) ​ (1,599) ​ ​ 320,819 ​ 333,836 Less: current maturities of long-term debt and other ​ (29,811) ​ (22,295) Long-term debt ​ $ 291,008 ​ $ 311,541

Related Party Transactions

Related Party Transactions	9 Months Ended
	Mar. 31, 2024
Related Party Transactions
Related Party Transactions	6. Related Party Transactions Certain relatives of Jack C. Bendheim, our Chairman, President and Chief Executive Officer, provided services to the Company as employees or consultants and received aggregate compensation and benefits of approximately $392 and $385 during the three months ended March 31, 2024 and 2023, and $1,209 and $1,561 during the nine months ended March 31, 2024 and 2023, respectively. Mr. Bendheim has sole authority to vote shares of our stock owned by BFI Co., LLC, an investment vehicle of the Bendheim family.

Stock Incentive Plan

Stock Incentive Plan	9 Months Ended
	Mar. 31, 2024
Stock Incentive Plan
Stock Incentive Plan	7. Stock Incentive Plan Restricted Stock Units Our Board of Directors has approved grants of 600,000 restricted stock units (“RSUs”) to certain officers of the Company, pursuant to the Company's 2008 Incentive Plan and the RSU award agreements. Each RSU represents the right to receive a share of our common stock upon vesting. Certain RSUs are subject to time-based vesting, and certain RSUs are subject to performance-based vesting. The time-based RSUs vest in five fourth fifth We used Monte Carlo simulation models to determine the grant date fair values of the performance-based RSUs. Assumptions used by the models were based on information as of the grant date and included a risk-free rate of return, expected volatility and an expected dividend yield. The risk-free rate of return is based on U.S. treasury yields for bonds with similar maturities. Expected volatility is based on the historical volatility of the Company’s common stock. The expected dividend yield considers estimated annual dividends and the grant date share price of the underlying common stock. The weighted-average grant date fair value of the RSUs granted in 2024 was $5.44 per share. We recognize stock-based compensation expense for the RSUs on a straight-line basis over the vesting periods. Stock-based compensation expense for the three and nine months ended March 31, 2024, was $135 and $296, respectively. At March 31, 2024, there was $2,967 of unrecognized compensation expense related to the RSUs, which will be recognized over a weighted-average period of 4.1 years.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Mar. 31, 2024
Commitments and Contingencies
Commitments and Contingencies	8. Commitments and Contingencies Environmental Our operations and properties are subject to extensive federal, state, local and foreign laws and regulations, including those governing pollution; protection of the environment; the use, management, and release of hazardous materials, substances and wastes; air emissions; greenhouse gas emissions; water use, supply and discharges; the investigation and remediation of contamination; the manufacture, distribution, and sale of regulated materials, including pesticides; the importing, exporting and transportation of products; and the health and safety of our employees (collectively, “Environmental Laws”). As such, the nature of our current and former operations exposes us to the risk of claims with respect to such matters, including fines, penalties, and remediation obligations that may be imposed by regulatory authorities. Under certain circumstances, we might be required to curtail operations until a particular problem is remedied. Known costs and expenses under Environmental Laws incidental to ongoing operations, including the cost of litigation proceedings relating to environmental matters, are included within operating results. Potential costs and expenses may also be incurred in connection with the repair or upgrade of facilities to meet existing or new requirements under Environmental Laws or to investigate or remediate potential or actual contamination, and from time to time we establish reserves for such contemplated investigation and remediation costs. In many instances, the ultimate costs under Environmental Laws and the period during which such costs are likely to be incurred are difficult to predict. While we believe that our operations are currently in material compliance with Environmental Laws, we have, from time to time, received notices of violation from governmental authorities and have been involved in civil or criminal action for such violations. Additionally, at various sites, our subsidiaries are engaged in continuing investigation, remediation and/or monitoring efforts to address contamination associated with historic operations of the sites. We devote considerable resources to complying with Environmental Laws and managing environmental liabilities. We have developed programs to identify requirements under, and maintain compliance with Environmental Laws; however, we cannot predict with certainty the effect of increased and more stringent regulation on our operations, future capital expenditure requirements, or the cost of compliance. The nature of our current and former operations exposes us to the risk of claims with respect to environmental matters and we cannot assure we will not incur material costs and liabilities in connection with such claims. Based on our experience, we believe that the future cost of compliance with existing Environmental Laws, and liabilities for known environmental claims pursuant to such Environmental Laws, will not have a material adverse effect on our financial position, results of operations, cash flows or liquidity. The United States Environmental Protection Agency (the “EPA”) is investigating and planning for the remediation of offsite contaminated groundwater that has migrated from the Omega Chemical Corporation Superfund Site (“Omega Chemical Site”), which is upgradient of the Santa Fe Springs, California facility of our subsidiary, Phibro-Tech, Inc. (“Phibro-Tech”). The EPA has entered into a settlement agreement with a group of companies that sent chemicals to the Omega Chemical Site for processing and recycling (“OPOG”) to remediate the contaminated groundwater that has migrated from the Omega Chemical Site in accordance with a general remedy selected by the EPA. The EPA has named Phibro-Tech and certain other subsidiaries of PAHC as potentially responsible parties (“PRPs”) due to groundwater contamination from Phibro-Tech’s Santa Fe Springs facility that has allegedly commingled with contaminated groundwater from the Omega Chemical Site. In September 2012, the EPA notified approximately 140 PRPs, including Phibro-Tech and the other subsidiaries, that they have been identified as potentially responsible for remedial action for the groundwater plume affected by the Omega Chemical Site and for EPA oversight and response costs. Phibro-Tech contends that any groundwater contamination at its site is localized and due to historical operations that pre-date Phibro-Tech and/or contaminated groundwater that has migrated from upgradient properties. In addition, a successor to a prior owner of the Phibro-Tech site has asserted that PAHC and Phibro-Tech are obligated to provide indemnification for its potential liability and defense costs relating to the groundwater plume affected by the Omega Chemical Site. PAHC and Phibro-Tech have vigorously contested this position and have asserted that the successor to the prior owner is required to indemnify Phibro-Tech for its potential liability and defense costs. In 2014, several members of OPOG filed a complaint under the Comprehensive Environmental Response, Compensation, and Liability Act (“CERCLA”) and the Resource Conservation and Recovery Act in the United States District Court for the Central District of California against many of the PRPs allegedly associated with the groundwater plume affected by the Omega Chemical Site (including Phibro-Tech) for contribution toward past and future costs associated with the investigation and remediation of the groundwater plume affected by the Omega Chemical Site. In August 2022, the United States Department of Justice (the “DOJ”), on behalf of the EPA, sent Phibro-Tech and certain other PRPs a pre-litigation notice letter regarding potential CERCLA Sec. 107 cost recovery claims seeking unrecovered past costs related to the groundwater plume affected by the Omega Chemical Site, along with a declaration allocating liability for future costs. In February 2023, the plaintiffs in the OPOG lawsuit and certain defendants in the OPOG lawsuit, including Phibro-Tech, signed a definitive settlement agreement that provides for a “cash-out” settlement, with contribution protection, for Phibro-Tech and its affiliates (as well as certain other defendants) releasing Phibro-Tech and its affiliates from liability for contamination of the groundwater plume affected by the Omega Chemical Site (with certain exceptions), including past and future EPA response costs that were the subject of the August 2022 pre-litigation notice letter sent by the DOJ on behalf of the EPA. As part of the settlement, Phibro-Tech also resolved all claims for indemnification and contribution between Phibro-Tech and the successor to the prior owner of the Phibro-Tech site. The definitive settlement agreement contemplates cash payments by Phibro-Tech and one of its affiliates. All cash payments have been made as of March 31, 2024. The definitive settlement agreement is subject to formal approval by the EPA, the DOJ and the district court. ​ Based upon information available, to the extent such costs can be estimated with reasonable certainty, we estimated the cost for further investigation and remediation of identified soil and groundwater problems at operating sites, closed sites and third-party sites, and closure costs for closed sites, including the remaining liability for the OPOG lawsuit described in the preceding paragraph, to be approximately $4,270 and $8,505 at March 31, 2024 and June 30, 2023, respectively, which is included in current and long-term liabilities on the consolidated balance sheets. However, future events, such as new information, changes in existing Environmental Laws or their interpretation, and more vigorous enforcement policies of regulatory agencies, may give rise to additional expenditures or liabilities that could be material. For all purposes of the discussion under this caption and elsewhere in this report, it should be noted that we take and have taken the position that neither PAHC nor any of our subsidiaries are liable for environmental or other claims made against one or more of our other subsidiaries or for which any of such other subsidiaries may ultimately be responsible. Claims and Litigation PAHC and its subsidiaries are party to various claims and lawsuits arising out of the normal course of business including product liabilities, payment disputes and governmental regulation. Certain of these actions seek damages in various amounts. In many cases, such claims are covered by insurance. We believe that none of the claims or pending lawsuits, either individually or in the aggregate, will have a material adverse effect on our financial position, results of operations, cash flows or liquidity.

Derivatives

Derivatives	9 Months Ended
	Mar. 31, 2024
Derivatives
Derivatives	9. Derivatives We monitor our exposure to foreign currency exchange rates and interest rates and from time-to-time use derivatives to manage certain of these risks. We designate derivatives as a hedge of a forecasted transaction or of the variability of the cash flows to be received or paid in the future related to a recognized asset or liability (cash flow hedge). All changes in the fair value of a highly effective cash flow hedge are recorded in Accumulated other comprehensive income (loss). We routinely assess whether the derivatives used to hedge transactions are effective. If we determine that a derivative ceases to be an effective hedge, we discontinue hedge accounting in the period of the assessment for that derivative, and immediately recognize any unrealized gains or losses related to the fair value of that derivative in the consolidated statements of operations. We record derivatives at fair value in the consolidated balance sheets. For additional details regarding fair value, see “Note 10 — Fair Value Measurements.” We are a party to an interest rate swap agreement on $300,000 of notional principal that effectively converts the floating SOFR portion of our interest obligation on that amount of debt to a fixed rate of 0.61% through June 2025 The consolidated balance sheet includes the net fair values of our outstanding foreign currency option contracts within the respective line items, based on the net financial position and maturity date of the individual contracts. The consolidated balance sheet includes the net fair values of our outstanding interest rate swap within the respective balance sheet line items, based on the expected timing of the cash flows. The consolidated balance sheet includes assets and liabilities for the fair values of outstanding derivatives that are designated and effective as cash flow hedges as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ June 30, As of 2024 2023 Other current assets ​ ​ Foreign currency option contracts, net ​ $ 467 ​ $ 333 Interest rate swap ​ 13,080 ​ 14,031 Other assets ​ ​ ​ ​ ​ ​ Interest rate swap ​ ​ 2,733 ​ ​ 10,225 Total Fair Value ​ ​ ​ ​ Foreign currency option contracts, net ​ 467 ​ 333 Interest rate swap ​ 15,813 ​ 24,256 ​ Notional amounts of the derivatives as of the balance sheet date were: ​ ​ ​ ​ ​ ​ ​ March 31, As of 2024 Interest rate swap ​ $ 300,000 Brazil Real-USD call options ​ R$ 18,000 Brazil Real-USD put options ​ R$ (18,000) USD-Israel shekel call options ​ $ (10,872) USD-Israel shekel put options ​ $ 10,872 ​ The consolidated statements of operations and statements of comprehensive income for the periods ended March 31, 2024 and 2023 included the effects of derivatives as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Nine Months ​ For the Periods Ended March 31 ​ 2024 2023 2024 2023 ​ Foreign currency option contracts, net ​ ​ ​ ​ ​ ​ (Income) expense recorded in consolidated statements of operations ​ $ (183) ​ $ 368 ​ $ (754) ​ $ 1,161 ​ Consolidated statement of operations - total cost of goods sold ​ $ 183,623 ​ $ 170,133 ​ $ 518,573 ​ $ 501,269 ​ Consolidated statement of operations - total selling, general and administrative expenses ​ $ 59,676 ​ $ 56,987 ​ $ 191,043 ​ $ 173,490 ​ (Income) expense recorded in comprehensive income ​ $ 875 ​ $ (83) ​ $ (35) ​ $ 67 ​ Interest rate swap ​ ​ ​ ​ ​ ​ ​ ​ ​ (Income) recorded in consolidated statements of operations ​ $ (3,646) ​ $ (2,994) ​ $ (10,859) ​ $ (6,502) ​ Consolidated statement of operations - total interest expense, net ​ $ 4,575 ​ $ 3,871 ​ $ 13,798 ​ $ 10,822 ​ (Income) expense recorded in comprehensive income ​ $ 918 ​ $ 3,848 ​ $ 8,442 ​ $ (1,871) ​ ​ We recognize gains and losses related to certain foreign currency derivatives as a component of cost of goods sold at the time the hedged item is sold. Inventory as of March 31, 2024, included realized net gains of $1,426 related to matured contracts. We anticipate the net gains included in inventory will be recognized in cost of goods sold within the next 18 months.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Mar. 31, 2024
Fair Value Measurements
Fair Value Measurements	10. Fair Value Measurements Short-term Investments Our short-term investments consist of cash deposits held at financial institutions. We consider the carrying amounts of these short-term investments to be representative of their fair value. Current Assets and Liabilities We consider the carrying amounts of current assets and current liabilities to be representative of their fair value because of the current nature of these items. Debt We record debt, including term loans and revolver balances, at amortized cost in our consolidated financial statements. We believe the carrying value of the debt is approximately equal to its fair value, due to the variable nature of the instruments and our evaluation of estimated market prices. Derivatives We determine the fair value of derivative instruments based upon pricing models using observable market inputs for these types of financial instruments, such as spot and forward currency exchange rates. Non-financial Assets Our non-financial assets, which primarily consist of goodwill, other intangible assets, property and equipment, and lease-related right-of-use (“ROU”) assets, are not required to be measured at fair value on a recurring basis, and instead are reported at carrying value in the consolidated balance sheet. Assets and liabilities may be required to be measured at fair value on a non-recurring basis, either upon initial recognition or for subsequent accounting or reporting, including the initial recognition of net assets acquired in a business combination. These fair value measurements involve unobservable inputs that reflect estimates and assumptions that represent Level 3 inputs. Fair Value of Assets (Liabilities) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of ​ March 31, 2024 ​ June 30, 2023 ​ Level 1 Level 2 Level 3 Level 1 Level 2 Level 3 Short-term investments ​ $ 48,523 ​ $ — ​ $ — ​ $ 40,000 ​ $ — ​ $ — Foreign currency derivatives ​ $ — ​ $ 467 ​ $ — ​ $ — ​ $ 333 ​ $ — Interest rate swap ​ $ — ​ $ 15,813 ​ $ — ​ $ — ​ $ 24,256 ​ $ — ​ There were no transfers between levels during the periods presented.

Business Segments

Business Segments	9 Months Ended
	Mar. 31, 2024
Business Segments
Business Segments	11. Business Segments We evaluate performance and allocate resources, based on the Animal Health, Mineral Nutrition and Performance Products segments. Certain of our costs and assets are not directly attributable to these segments and we refer to these items as Corporate. We do not allocate Corporate costs or assets to the segments because they are not used to evaluate the segments’ operating results or financial position. Corporate costs include certain costs related to executive management, business technology, legal, finance, human resources and business development. The accounting policies of our segments are the same as those described in the summary of significant accounting policies included herein. ​ We evaluate performance of our segments based on Adjusted EBITDA. We calculate Adjusted EBITDA as net income plus (a) interest expense, net, (b) provision for income taxes or less benefit for income taxes, (c) depreciation and amortization, (d) other expense or less other income as separately reported on our consolidated statements of operations, including foreign currency (gains) losses, net and (e) certain items that we consider to be unusual, non-operational or non-recurring. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Nine Months For the Periods Ended March 31 2024 2023 2024 2023 Net sales Animal Health ​ $ 181,333 ​ $ 164,434 ​ $ 514,967 ​ $ 483,096 Mineral Nutrition ​ 64,228 ​ 62,922 ​ 181,601 ​ 184,212 Performance Products ​ 17,662 ​ 18,317 ​ 47,947 ​ 55,532 Total segments ​ $ 263,223 ​ $ 245,673 ​ $ 744,515 ​ $ 722,840 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Depreciation and amortization ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Animal Health ​ $ 7,695 ​ $ 6,888 ​ $ 22,392 ​ $ 20,733 Mineral Nutrition ​ 601 ​ 671 ​ 1,907 ​ 1,985 Performance Products ​ 432 ​ 453 ​ 1,291 ​ 1,348 Total segments ​ $ 8,728 ​ $ 8,012 ​ $ 25,590 ​ $ 24,066 Adjusted EBITDA ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Animal Health ​ $ 36,524 ​ $ 34,217 ​ $ 104,317 ​ $ 98,240 Mineral Nutrition ​ 4,665 ​ 3,859 ​ 11,053 ​ 13,555 Performance Products ​ 2,371 ​ 2,413 ​ 4,597 ​ 7,069 Total segments ​ $ 43,560 ​ $ 40,489 ​ $ 119,967 ​ $ 118,864 Reconciliation of income before income taxes to Adjusted EBITDA ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Income before income taxes ​ $ 12,922 ​ $ 15,104 ​ $ 4,508 ​ $ 32,630 Interest expense, net ​ 4,575 ​ 3,871 ​ 13,798 ​ 10,822 Depreciation and amortization – Total segments ​ 8,728 ​ 8,012 ​ 25,590 ​ 24,066 Depreciation and amortization – Corporate ​ 468 ​ 477 ​ 1,387 ​ 1,372 Corporate costs ​ ​ 13,856 ​ ​ 13,122 ​ ​ 42,160 ​ ​ 38,451 Acquisition-related cost of goods sold ​ ​ 211 ​ ​ — ​ ​ 521 ​ ​ — Acquisition-related other ​ ​ 512 ​ ​ — ​ ​ 512 ​ ​ — Pension settlement cost ​ ​ — ​ ​ — ​ ​ 10,674 ​ ​ — Brazil employment taxes ​ ​ — ​ ​ — ​ ​ 4,202 ​ ​ — Insurance proceeds ​ ​ (274) ​ ​ — ​ ​ (274) ​ ​ — Stock-based compensation ​ ​ 135 ​ ​ — ​ ​ 296 ​ ​ — Environmental remediation costs ​ ​ — ​ ​ 325 ​ ​ — ​ ​ 6,894 Foreign currency losses (gains), net ​ 2,427 ​ (422) ​ 16,593 ​ 4,629 Adjusted EBITDA – Total segments ​ $ 43,560 ​ $ 40,489 ​ $ 119,967 ​ $ 118,864 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, June 30, As of 2024 2023 Identifiable assets ​ ​ Animal Health ​ $ 701,252 ​ $ 698,522 Mineral Nutrition ​ 69,846 ​ 75,814 Performance Products ​ 49,275 ​ 49,678 Total segments ​ 820,373 ​ 824,014 Corporate ​ 158,662 ​ 147,383 Total ​ $ 979,035 ​ $ 971,397 ​ The Animal Health segment includes all goodwill of the Company. Corporate assets include cash and cash equivalents, short-term investments, debt issuance costs, income tax-related assets and certain other assets.

Subsequent Event

Subsequent Event	9 Months Ended
	Mar. 31, 2024
Subsequent Event
Subsequent Event	12. Subsequent Event – Agreement to Acquire an MFA product portfolio and related assets ​ In April 2024, we entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with Zoetis Inc. to acquire Zoetis’ medicated feed additive (MFA) product portfolio, certain water soluble products and related assets. The purchase price is $350,000 subject to certain adjustments set forth in the Purchase Agreement, payable in cash at closing. The closing of the transaction is subject to certain customary conditions. We plan to finance the transaction with approximately $325,000 of new debt and, to the extent necessary, balance sheet cash. In connection with the Purchase Agreement, we entered into a debt commitment letter pursuant to which certain financial institutions have committed to provide a senior secured incremental first lien term loan facility in an aggregate principal amount of $325,000. The funding of the incremental first lien term loan facility is contingent on the satisfaction of certain customary conditions.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies and New Accounting Standards (Policies)	9 Months Ended
	Mar. 31, 2024
Summary of Significant Accounting Policies and New Accounting Standards
Net Income per Share and Weighted Average Shares	Net Income per Share and Weighted Average Shares Basic net income per share is calculated by dividing net income by the weighted average number of common shares outstanding during the reporting period. Diluted net income per share is calculated by dividing net income by the weighted average number of common shares outstanding during the reporting period after giving effect to dilutive common share equivalents, resulting from the assumed vesting of restricted stock units, unless the effect would be antidilutive. Common share equivalents were included in the calculation of diluted net income per share for the three and nine months ended March 31, 2024. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months ​ Nine Months ​ For the Periods Ended March 31 2024 2023 2024 2023 Net income ​ $ 8,405 ​ $ 10,042 ​ $ 1,664 ​ $ 21,108 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average number of shares – basic ​ 40,504 ​ 40,504 ​ 40,504 ​ 40,504 ​ Dilutive effect of restricted stock units ​ ​ 16 ​ ​ — ​ ​ 5 ​ ​ — ​ Weighted average number of shares - diluted ​ ​ 40,520 ​ ​ 40,504 ​ ​ 40,509 ​ ​ 40,504 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net income per share ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ basic ​ $ 0.21 ​ $ 0.25 ​ $ 0.04 ​ $ 0.52 ​ diluted ​ $ 0.21 ​ $ 0.25 ​ $ 0.04 ​ $ 0.52 ​
New Accounting Standards	New Accounting Standards Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, ​ ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures,

Summary of Significant Accoun_3

Summary of Significant Accounting Policies and New Accounting Standards (Tables)	9 Months Ended
	Mar. 31, 2024
Summary of Significant Accounting Policies and New Accounting Standards
Schedule of net income per share and weighted average shares	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months ​ Nine Months ​ For the Periods Ended March 31 2024 2023 2024 2023 Net income ​ $ 8,405 ​ $ 10,042 ​ $ 1,664 ​ $ 21,108 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average number of shares – basic ​ 40,504 ​ 40,504 ​ 40,504 ​ 40,504 ​ Dilutive effect of restricted stock units ​ ​ 16 ​ ​ — ​ ​ 5 ​ ​ — ​ Weighted average number of shares - diluted ​ ​ 40,520 ​ ​ 40,504 ​ ​ 40,509 ​ ​ 40,504 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net income per share ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ basic ​ $ 0.21 ​ $ 0.25 ​ $ 0.04 ​ $ 0.52 ​ diluted ​ $ 0.21 ​ $ 0.25 ​ $ 0.04 ​ $ 0.52 ​

Statements of Operations-Addi_2

Statements of Operations-Additional Information (Tables)	9 Months Ended
	Mar. 31, 2024
Statements of Operations-Additional Information
Schedule of revenues disaggregated by major product category and geographic region	Net Sales by Product Type ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months ​ Nine Months For the Periods Ended March 31 2024 2023 2024 2023 Animal Health ​ ​ ​ ​ ​ MFAs and other ​ $ 108,216 ​ $ 93,217 ​ $ 304,261 ​ $ 283,186 Nutritional specialties ​ 40,194 ​ 45,016 ​ 121,840 ​ 127,926 Vaccines ​ 32,923 ​ 26,201 ​ 88,866 ​ 71,984 Total Animal Health ​ $ 181,333 ​ $ 164,434 ​ $ 514,967 ​ $ 483,096 Mineral Nutrition ​ 64,228 ​ 62,922 ​ 181,601 ​ 184,212 Performance Products ​ 17,662 ​ 18,317 ​ 47,947 ​ 55,532 Total ​ $ 263,223 ​ $ 245,673 ​ $ 744,515 ​ $ 722,840 ​ Net Sales by Region ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months ​ Nine Months For the Periods Ended March 31 2024 2023 2024 2023 United States ​ $ 159,314 ​ $ 148,529 ​ $ 431,083 ​ $ 433,716 Latin America and Canada ​ 53,653 ​ 53,881 ​ 177,539 ​ 159,946 Europe, Middle East and Africa ​ 33,175 ​ 28,174 ​ 89,572 ​ 85,518 Asia Pacific ​ 17,081 ​ 15,089 ​ 46,321 ​ 43,660 Total ​ $ 263,223 ​ $ 245,673 ​ $ 744,515 ​ $ 722,840
Schedule of interest expense, net	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months ​ Nine Months ​ For the Periods Ended March 31 2024 2023 2024 2023 ​ Interest expense, net ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2021 Credit Facilities ​ $ 5,127 ​ $ 4,517 ​ $ 15,421 ​ $ 12,316 ​ 2022 Term Loan ​ ​ 215 ​ ​ 191 ​ ​ 648 ​ ​ 379 ​ Amortization of debt issuance costs ​ 260 ​ 188 ​ 780 ​ 514 ​ Other ​ 43 ​ 10 ​ 164 ​ 20 ​ Interest expense ​ 5,645 ​ 4,906 ​ 17,013 ​ 13,229 ​ Interest income ​ (1,070) ​ (1,035) ​ (3,215) ​ (2,407) ​ ​ ​ $ 4,575 ​ $ 3,871 ​ $ 13,798 ​ $ 10,822 ​ ​
Schedule of depreciation and amortization	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months ​ Nine Months For the Periods Ended March 31 2024 2023 2024 2023 Depreciation and amortization ​ ​ ​ ​ ​ ​ Depreciation of property, plant and equipment ​ $ 6,770 ​ $ 6,067 ​ $ 19,638 ​ $ 18,177 Amortization of intangible assets ​ 2,426 ​ 2,422 ​ 7,339 ​ 7,261 ​ ​ $ 9,196 ​ $ 8,489 ​ $ 26,977 ​ $ 25,438

Balance Sheets-Additional Inf_2

Balance Sheets-Additional Information (Tables)	9 Months Ended
	Mar. 31, 2024
Balance Sheets-Additional Information
Schedule of inventories	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ June 30, As of 2024 2023 Inventories ​ ​ ​ ​ ​ Raw materials ​ $ 75,638 ​ $ 84,328 Work-in-process ​ ​ 26,110 ​ ​ 22,350 Finished goods ​ ​ 180,541 ​ ​ 170,892 ​ ​ $ 282,289 ​ $ 277,570
Schedule of other assets	​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ June 30, As of 2024 2023 Other assets ​ ​ ​ ​ ​ ​ ROU operating lease assets ​ $ 37,100 $ 35,759 Deferred income taxes ​ 14,506 ​ 8,711 Deposits ​ 2,338 ​ 6,617 Insurance investments ​ 6,171 ​ 6,067 Equity method investments ​ 5,081 ​ 5,027 Derivative instruments ​ ​ 2,733 ​ ​ 10,225 Debt issuance costs ​ 1,035 ​ 1,408 Other ​ ​ 7,947 ​ ​ 8,031 ​ ​ $ 76,911 $ 81,845
Schedule of accrued expenses and other current liabilities	​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, June 30, As of 2024 2023 Accrued expenses and other current liabilities ​ ​ Employee related ​ $ 30,908 ​ $ 29,359 Current operating lease liabilities ​ 7,107 ​ 6,053 Commissions and rebates ​ ​ 5,953 ​ ​ 5,833 Professional fees ​ 7,581 ​ 5,032 Income and other taxes ​ ​ 5,294 ​ ​ 8,663 Insurance-related ​ 1,397 ​ 1,284 Insurance premium financing ​ ​ 661 ​ ​ 4,769 Other ​ 17,747 ​ 18,859 ​ ​ $ 76,648 ​ $ 79,852
Schedule of other liabilities	​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, June 30, As of 2024 2023 Other liabilities ​ ​ ​ ​ ​ ​ Long-term operating lease liabilities ​ $ 30,062 ​ $ 29,077 Long-term and deferred income taxes ​ 15,106 ​ ​ 12,146 Supplemental retirement benefits, deferred compensation and other ​ ​ 6,768 ​ ​ 6,552 U.S. pension plan, net ​ 1,644 ​ 2,286 International retirement plans ​ 3,282 ​ 4,210 Other long-term liabilities ​ 6,999 ​ 6,076 ​ ​ $ 63,861 ​ $ 60,347
Schedule of accumulated other comprehensive loss	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, June 30, As of 2024 2023 Accumulated other comprehensive loss ​ ​ ​ ​ Derivative instruments ​ $ 16,182 ​ $ 24,589 Foreign currency translation adjustment ​ (117,249) ​ (115,062) Unrecognized net pension losses ​ (12,485) ​ (23,996) Income tax (provision) benefit ​ (452) ​ 259 ​ ​ $ (114,004) ​ $ (114,210)

Debt (Tables)

Debt (Tables)	9 Months Ended
	Mar. 31, 2024
Debt
Schedule of long term debt	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine Months ​ ​ March 31, June 30, ​ Ended March 31 ​ ​ 2024 2023 ​ 2024 ​ 2023 ​ 2021 Revolver 6.09 % 6.09 % 6.17 % 5.07 % 2021 Term A Loan ​ 2.36 % 2.36 % ​ 2.36 % 2.37 % 2023 Incremental Term Loan ​ 7.69 % 7.44 % ​ 7.63 % — ​ 2022 Term Loan ​ 7.43 % 7.25 % ​ 7.41 % 6.07 % ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ June 30, As of ​ 2024 ​ 2023 2021 Term A Loan due April 2026 ​ $ 262,500 ​ $ 273,750 2023 Incremental Term Loan due April 2026 ​ ​ 46,250 ​ ​ 50,000 2022 Term Loan due September 2027 ​ ​ 11,370 ​ ​ 11,685 Other ​ 1,891 ​ — ​ ​ 322,011 ​ 335,435 Unamortized debt issuance costs ​ (1,192) ​ (1,599) ​ ​ 320,819 ​ 333,836 Less: current maturities of long-term debt and other ​ (29,811) ​ (22,295) Long-term debt ​ $ 291,008 ​ $ 311,541

Derivatives (Tables)

Derivatives (Tables)	9 Months Ended
	Mar. 31, 2024
Derivatives
Schedule of significant outstanding derivatives employed to manage market risk and designated as cash flow hedges	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ June 30, As of 2024 2023 Other current assets ​ ​ Foreign currency option contracts, net ​ $ 467 ​ $ 333 Interest rate swap ​ 13,080 ​ 14,031 Other assets ​ ​ ​ ​ ​ ​ Interest rate swap ​ ​ 2,733 ​ ​ 10,225 Total Fair Value ​ ​ ​ ​ Foreign currency option contracts, net ​ 467 ​ 333 Interest rate swap ​ 15,813 ​ 24,256 ​ Notional amounts of the derivatives as of the balance sheet date were: ​ ​ ​ ​ ​ ​ ​ March 31, As of 2024 Interest rate swap ​ $ 300,000 Brazil Real-USD call options ​ R$ 18,000 Brazil Real-USD put options ​ R$ (18,000) USD-Israel shekel call options ​ $ (10,872) USD-Israel shekel put options ​ $ 10,872
Schedule of effects of derivatives	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Nine Months ​ For the Periods Ended March 31 ​ 2024 2023 2024 2023 ​ Foreign currency option contracts, net ​ ​ ​ ​ ​ ​ (Income) expense recorded in consolidated statements of operations ​ $ (183) ​ $ 368 ​ $ (754) ​ $ 1,161 ​ Consolidated statement of operations - total cost of goods sold ​ $ 183,623 ​ $ 170,133 ​ $ 518,573 ​ $ 501,269 ​ Consolidated statement of operations - total selling, general and administrative expenses ​ $ 59,676 ​ $ 56,987 ​ $ 191,043 ​ $ 173,490 ​ (Income) expense recorded in comprehensive income ​ $ 875 ​ $ (83) ​ $ (35) ​ $ 67 ​ Interest rate swap ​ ​ ​ ​ ​ ​ ​ ​ ​ (Income) recorded in consolidated statements of operations ​ $ (3,646) ​ $ (2,994) ​ $ (10,859) ​ $ (6,502) ​ Consolidated statement of operations - total interest expense, net ​ $ 4,575 ​ $ 3,871 ​ $ 13,798 ​ $ 10,822 ​ (Income) expense recorded in comprehensive income ​ $ 918 ​ $ 3,848 ​ $ 8,442 ​ $ (1,871) ​

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Mar. 31, 2024
Fair Value Measurements
Schedule of fair value of assets and liabilities measured on a recurring basis	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of ​ March 31, 2024 ​ June 30, 2023 ​ Level 1 Level 2 Level 3 Level 1 Level 2 Level 3 Short-term investments ​ $ 48,523 ​ $ — ​ $ — ​ $ 40,000 ​ $ — ​ $ — Foreign currency derivatives ​ $ — ​ $ 467 ​ $ — ​ $ — ​ $ 333 ​ $ — Interest rate swap ​ $ — ​ $ 15,813 ​ $ — ​ $ — ​ $ 24,256 ​ $ —

Business Segments (Tables)

Business Segments (Tables)	9 Months Ended
	Mar. 31, 2024
Business Segments
Schedule of information regarding reportable segments	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Nine Months For the Periods Ended March 31 2024 2023 2024 2023 Net sales Animal Health ​ $ 181,333 ​ $ 164,434 ​ $ 514,967 ​ $ 483,096 Mineral Nutrition ​ 64,228 ​ 62,922 ​ 181,601 ​ 184,212 Performance Products ​ 17,662 ​ 18,317 ​ 47,947 ​ 55,532 Total segments ​ $ 263,223 ​ $ 245,673 ​ $ 744,515 ​ $ 722,840 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Depreciation and amortization ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Animal Health ​ $ 7,695 ​ $ 6,888 ​ $ 22,392 ​ $ 20,733 Mineral Nutrition ​ 601 ​ 671 ​ 1,907 ​ 1,985 Performance Products ​ 432 ​ 453 ​ 1,291 ​ 1,348 Total segments ​ $ 8,728 ​ $ 8,012 ​ $ 25,590 ​ $ 24,066 Adjusted EBITDA ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Animal Health ​ $ 36,524 ​ $ 34,217 ​ $ 104,317 ​ $ 98,240 Mineral Nutrition ​ 4,665 ​ 3,859 ​ 11,053 ​ 13,555 Performance Products ​ 2,371 ​ 2,413 ​ 4,597 ​ 7,069 Total segments ​ $ 43,560 ​ $ 40,489 ​ $ 119,967 ​ $ 118,864 Reconciliation of income before income taxes to Adjusted EBITDA ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Income before income taxes ​ $ 12,922 ​ $ 15,104 ​ $ 4,508 ​ $ 32,630 Interest expense, net ​ 4,575 ​ 3,871 ​ 13,798 ​ 10,822 Depreciation and amortization – Total segments ​ 8,728 ​ 8,012 ​ 25,590 ​ 24,066 Depreciation and amortization – Corporate ​ 468 ​ 477 ​ 1,387 ​ 1,372 Corporate costs ​ ​ 13,856 ​ ​ 13,122 ​ ​ 42,160 ​ ​ 38,451 Acquisition-related cost of goods sold ​ ​ 211 ​ ​ — ​ ​ 521 ​ ​ — Acquisition-related other ​ ​ 512 ​ ​ — ​ ​ 512 ​ ​ — Pension settlement cost ​ ​ — ​ ​ — ​ ​ 10,674 ​ ​ — Brazil employment taxes ​ ​ — ​ ​ — ​ ​ 4,202 ​ ​ — Insurance proceeds ​ ​ (274) ​ ​ — ​ ​ (274) ​ ​ — Stock-based compensation ​ ​ 135 ​ ​ — ​ ​ 296 ​ ​ — Environmental remediation costs ​ ​ — ​ ​ 325 ​ ​ — ​ ​ 6,894 Foreign currency losses (gains), net ​ 2,427 ​ (422) ​ 16,593 ​ 4,629 Adjusted EBITDA – Total segments ​ $ 43,560 ​ $ 40,489 ​ $ 119,967 ​ $ 118,864 ​
Schedule of identifiable assets	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, June 30, As of 2024 2023 Identifiable assets ​ ​ Animal Health ​ $ 701,252 ​ $ 698,522 Mineral Nutrition ​ 69,846 ​ 75,814 Performance Products ​ 49,275 ​ 49,678 Total segments ​ 820,373 ​ 824,014 Corporate ​ 158,662 ​ 147,383 Total ​ $ 979,035 ​ $ 971,397

Summary of Significant Accoun_4

Summary of Significant Accounting Policies and New Accounting Standards (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Net Income (Loss) per Share and Weighted Average Shares
Net Income (Loss)	$ 8,405	$ 10,042	$ 1,664	$ 21,108
Net income - basic	8,405	10,042	1,664	21,108
Net income - diluted	$ 8,405	$ 10,042	$ 1,664	$ 21,108
Weighted average number of shares
Weighted average number of shares - basic (in shares)	40,504	40,504	40,504	40,504
Dilutive effect of restricted stock units (in shares)	16		5
Weighted average number of shares - diluted (in shares)	40,520	40,504	40,509	40,504
Net income per share
basic (in dollars per share)	$ 0.21	$ 0.25	$ 0.04	$ 0.52
diluted (in dollars per share)	$ 0.21	$ 0.25	$ 0.04	$ 0.52

Statements of Operations-Addi_3

Statements of Operations-Additional Information - Segments (Details) - segment	3 Months Ended		9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Business Segments
Number of reportable segments	3	3	3	3

Statements of Operations-Addi_4

Statements of Operations-Additional Information - Net Sales by Product Type (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Net sales
Net sales	$ 263,223	$ 245,673	$ 744,515	$ 722,840
Animal Health
Net sales
Net sales	181,333	164,434	514,967	483,096
MFAs and other
Net sales
Net sales	108,216	93,217	304,261	283,186
Nutritional Specialties
Net sales
Net sales	40,194	45,016	121,840	127,926
Vaccines
Net sales
Net sales	32,923	26,201	88,866	71,984
Mineral Nutrition
Net sales
Net sales	64,228	62,922	181,601	184,212
Performance Products
Net sales
Net sales	$ 17,662	$ 18,317	$ 47,947	$ 55,532

Statements of Operations-Addi_5

Statements of Operations-Additional Information - Net Sales by Region (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Net sales
Net sales	$ 263,223	$ 245,673	$ 744,515	$ 722,840
United States
Net sales
Net sales	159,314	148,529	431,083	433,716
Latin America and Canada
Net sales
Net sales	53,653	53,881	177,539	159,946
Europe, Middle East and Africa
Net sales
Net sales	33,175	28,174	89,572	85,518
Asia Pacific
Net sales
Net sales	$ 17,081	$ 15,089	$ 46,321	$ 43,660

Statements of Operations-Addi_6

Statements of Operations-Additional Information - General Information (Details)	9 Months Ended
	Mar. 31, 2024
Statements of Operations-Additional Information
Payment term, minimum	30 days
Payment term, maximum	120 days
Average worldwide collection period for accounts receivable	60 days

Statements of Operations-Addi_7

Statements of Operations-Additional Information - Interest Expense, Net (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Interest expense, net
Amortization of debt issuance costs	$ 260	$ 188	$ 780	$ 514
Other	43	10	164	20
Interest expense	5,645	4,906	17,013	13,229
Interest income	(1,070)	(1,035)	(3,215)	(2,407)
Interest expense, net	4,575	3,871	13,798	10,822
Credit Facilities
Interest expense, net
Interest expense, excluding amortization	5,127	4,517	15,421	12,316
2022 Term Loan
Interest expense, net
Interest expense, excluding amortization	$ 215	$ 191	$ 648	$ 379

Statements of Operations-Addi_8

Statements of Operations-Additional Information - Depreciation and Amortization (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Depreciation and amortization
Depreciation of property, plant and equipment	$ 6,770	$ 6,067	$ 19,638	$ 18,177
Amortization of intangible assets	2,426	2,422	7,339	7,261
Depreciation and amortization	$ 9,196	$ 8,489	$ 26,977	$ 25,438

Statements of Operations-Addi_9

Statements of Operations-Additional Information - Annuity Purchase Agreement (Details) - USD ($) $ in Thousands	1 Months Ended	9 Months Ended
	Jul. 31, 2023	Mar. 31, 2024
Statements of Operations-Additional Information
Annuity purchase price	$ 26,381
Pension settlement cost		$ 10,674

Balance Sheets-Additional Inf_3

Balance Sheets-Additional Information - Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Jun. 30, 2023
Inventories, net
Raw materials	$ 75,638	$ 84,328
Work-in-process	26,110	22,350
Finished goods	180,541	170,892
Inventory, net	$ 282,289	$ 277,570

Balance Sheets-Additional Inf_4

Balance Sheets-Additional Information - Other Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Jun. 30, 2023
Other assets
ROU operating lease assets	$ 37,100	$ 35,759
Deferred income taxes	14,506	8,711
Deposits	2,338	6,617
Insurance investments	6,171	6,067
Equity method investments	5,081	5,027
Derivative instruments	2,733	10,225
Debt issuance costs	1,035	1,408
Other	7,947	8,031
Other assets, total	$ 76,911	$ 81,845
Operating Lease, Right-of-Use Asset, Statement of Financial Position	Other assets, total	Other assets, total
Derivative Asset, Noncurrent, Statement of Financial Position	Other assets, total	Other assets, total

Balance Sheets-Additional Inf_5

Balance Sheets-Additional Information - Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Jun. 30, 2023
Accrued expenses and other current liabilities
Employee related	$ 30,908	$ 29,359
Current operating lease liabilities	7,107	6,053
Commissions and rebates	5,953	5,833
Professional fees	7,581	5,032
Income and other taxes	5,294	8,663
Insurance-related	1,397	1,284
Insurance premium financing	661	4,769
Other	17,747	18,859
Accrued expenses and other current liabilities, total	$ 76,648	$ 79,852
Operating Lease, Liability, Current, Statement of Financial Position	Accrued expenses and other current liabilities, total	Accrued expenses and other current liabilities, total

Balance Sheets-Additional Inf_6

Balance Sheets-Additional Information - Other Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Jun. 30, 2023
Other liabilities
Long-term operating lease liabilities	$ 30,062	$ 29,077
Long term and deferred income taxes	15,106	12,146
Supplemental retirement benefits, deferred compensation and other	6,768	6,552
U.S. pension plan, net	1,644	2,286
International retirement plans	3,282	4,210
Other long-term liabilities	6,999	6,076
Other liabilities, total	$ 63,861	$ 60,347
Operating Lease, Liability, Noncurrent, Statement of Financial Position	Other liabilities, total	Other liabilities, total

Balance Sheets-Additional Inf_7

Balance Sheets-Additional Information - Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Jun. 30, 2023
Accumulated other comprehensive loss
Accumulated other comprehensive loss, tax	$ (452)	$ 259
Accumulated other comprehensive loss	(114,004)	(114,210)
Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent
Accumulated other comprehensive loss
Accumulated other comprehensive loss, before tax	16,182	24,589
Accumulated Foreign Currency Adjustment Attributable to Parent
Accumulated other comprehensive loss
Accumulated other comprehensive loss, before tax	(117,249)	(115,062)
Accumulated Defined Benefit Plans Adjustment Attributable to Parent
Accumulated other comprehensive loss
Accumulated other comprehensive loss, before tax	$ (12,485)	$ (23,996)

Debt - General Information (Det

Debt - General Information (Details) $ in Thousands	1 Months Ended	3 Months Ended	9 Months Ended
	Sep. 30, 2022 USD ($)	Sep. 30, 2022 USD ($)	Mar. 31, 2024 USD ($)	Jun. 30, 2023 USD ($)	Nov. 30, 2022 USD ($)	Apr. 30, 2021 USD ($)
Line of Credit | Credit Facilities
Debt
Line of credit facility, expiration date			Apr. 30, 2026
Maximum First Lien Net Leverage Ratio			4
Maximum First Lien Net Leverage Ratio, Test Period			4.25
Minimum interest coverage ratio			3
Line of Credit | Credit Facilities | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Debt Instrument, Basis Spread on Variable Rate, Scenario One
Debt
Basis spread on variable rate (as a percent)			1.50%
Line of Credit | Credit Facilities | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Debt Instrument, Basis Spread on Variable Rate, Scenario Two
Debt
Basis spread on variable rate (as a percent)			1.75%
Line of Credit | Credit Facilities | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Debt Instrument, Basis Spread on Variable Rate, Scenario Three
Debt
Basis spread on variable rate (as a percent)			2%
Line of Credit | Credit Facilities | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Debt Instrument, Basis Spread on Variable Rate, Scenario Four
Debt
Basis spread on variable rate (as a percent)			2.25%
Line of Credit | Credit Facilities | Base Rate | Debt Instrument, Basis Spread on Variable Rate, Scenario One
Debt
Basis spread on variable rate (as a percent)			0.50%
Line of Credit | Credit Facilities | Base Rate | Debt Instrument, Basis Spread on Variable Rate, Scenario Two
Debt
Basis spread on variable rate (as a percent)			0.75%
Line of Credit | Credit Facilities | Base Rate | Debt Instrument, Basis Spread on Variable Rate, Scenario Three
Debt
Basis spread on variable rate (as a percent)			1%
Line of Credit | Credit Facilities | Base Rate | Debt Instrument, Basis Spread on Variable Rate, Scenario Four
Debt
Basis spread on variable rate (as a percent)			1.25%
Loans Payable | Term A Loan
Debt
Aggregate principal amount						$ 300,000
Loans Payable | 2023 Incremental Term Loan due April 2026
Debt
Aggregate principal amount				$ 50,000
Loans Payable | 2023 Incremental Term Loan due April 2026 | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Debt Instrument, Basis Spread on Variable Rate, Scenario One
Debt
Basis spread on variable rate (as a percent)			2%
Loans Payable | 2023 Incremental Term Loan due April 2026 | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Debt Instrument, Basis Spread on Variable Rate, Scenario Two
Debt
Basis spread on variable rate (as a percent)			2.25%
Loans Payable | 2023 Incremental Term Loan due April 2026 | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Debt Instrument, Basis Spread on Variable Rate, Scenario Three
Debt
Basis spread on variable rate (as a percent)			2.50%
Loans Payable | 2023 Incremental Term Loan due April 2026 | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Debt Instrument, Basis Spread on Variable Rate, Scenario Four
Debt
Basis spread on variable rate (as a percent)			2.75%
Loans Payable | 2023 Incremental Term Loan due April 2026 | Base Rate | Debt Instrument, Basis Spread on Variable Rate, Scenario One
Debt
Basis spread on variable rate (as a percent)			1%
Loans Payable | 2023 Incremental Term Loan due April 2026 | Base Rate | Debt Instrument, Basis Spread on Variable Rate, Scenario Two
Debt
Basis spread on variable rate (as a percent)			1.25%
Loans Payable | 2023 Incremental Term Loan due April 2026 | Base Rate | Debt Instrument, Basis Spread on Variable Rate, Scenario Three
Debt
Basis spread on variable rate (as a percent)			1.50%
Loans Payable | 2023 Incremental Term Loan due April 2026 | Base Rate | Debt Instrument, Basis Spread on Variable Rate, Scenario Four
Debt
Basis spread on variable rate (as a percent)			1.75%
Revolving Credit Facility | Revolver
Debt
Maximum borrowing capacity					$ 310,000	$ 250,000
Aggregate available credit facilities			$ 142,706
Outstanding borrowings			165,000
Letter of Credit
Debt
Letters of credit outstanding			$ 2,294
Debt instrument, term			1 year
Secured Debt | 2022 Term Loan
Debt
Aggregate principal amount	$ 12,000	$ 12,000
Debt instrument, periodic payment		$ 35
Debt instrument, frequency of periodic payment		monthly
Secured Debt | 2022 Term Loan | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate
Debt
Basis spread on variable rate (as a percent)	2%
Secured Debt | 2022 Term Loan | Fed Funds Effective Rate Overnight Index Swap Rate
Debt
Basis spread on variable rate (as a percent)			0.50%

Debt - Interest Rates - Stated

Debt - Interest Rates - Stated Rates (Details)	Mar. 31, 2024	Jun. 30, 2023
Revolving Credit Facility | Revolver
Debt
Interest rate (as a percent)	6.09%	6.09%
Loans Payable | Term A Loan
Debt
Interest rate (as a percent)	2.36%	2.36%
Loans Payable | 2023 Incremental Term Loan due April 2026
Debt
Interest rate (as a percent)	7.69%	7.44%
Secured Debt | 2022 Term Loan
Debt
Interest rate (as a percent)	7.43%	7.25%

Debt - Interest Rates - Weighte

Debt - Interest Rates - Weighted Average Rates (Details)	9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revolving Credit Facility | Revolver
Debt
Long-term debt, weighted average interest rate, over time	6.17%	5.07%
Loans Payable | Term A Loan
Debt
Long-term debt, weighted average interest rate, over time	2.36%	2.37%
Loans Payable | 2023 Incremental Term Loan due April 2026
Debt
Long-term debt, weighted average interest rate, over time	7.63%
Secured Debt | 2022 Term Loan
Debt
Long-term debt, weighted average interest rate, over time	7.41%	6.07%

Debt - Derivatives (Details)

Debt - Derivatives (Details) - Cash Flow Hedging - USD ($) $ in Thousands	1 Months Ended
	Jul. 31, 2022	Mar. 31, 2024
Interest Rate Swap
Derivatives
Derivative, notional amount		$ 300,000
Interest Rate Swap, July 2022
Derivatives
Derivative, notional amount	$ 300,000
Derivative, fixed interest rate (as a percent)	0.61%
Derivative, maturity date	Jun. 30, 2025

Debt - Reconciliation (Details)

Debt - Reconciliation (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Jun. 30, 2023
Debt Maturities
Other	$ 1,891
Total long-term debt and short-term debt, gross	322,011	$ 335,435
Unamortized debt issuance costs	(1,192)	(1,599)
Total long-term debt and short-term debt	320,819	333,836
Loans Payable | Term A Loan
Debt Maturities
Long-term debt, gross	262,500	273,750
Loans Payable | 2023 Incremental Term Loan due April 2026
Debt Maturities
Long-term debt, gross	46,250	50,000
Secured Debt | 2022 Term Loan
Debt Maturities
Long-term debt, gross	$ 11,370	$ 11,685

Debt - Classification (Details)

Debt - Classification (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Jun. 30, 2023
Debt Maturities
Total long-term debt and short-term debt	$ 320,819	$ 333,836
Less: current maturities of long-term debt and other	(29,811)	(22,295)
Long-term debt, non-current	$ 291,008	$ 311,541

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Immediate Family Member of Management or Principal Owner | Compensation and Benefit for Services
Related Party Transactions
Aggregate compensation and benefits	$ 392	$ 385	$ 1,209	$ 1,561

Stock Incentive Plan - Restrict

Stock Incentive Plan - Restricted Stock Units (Details) - $ / shares	1 Months Ended		9 Months Ended
	Feb. 29, 2024	Jul. 31, 2023	Mar. 31, 2024
Restricted Stock Units (RSUs)
Stock Incentive Plan
Grant date fair value (in dollars per share)			$ 5.44
Restricted Stock Units (RSUs) | July 2023
Stock Incentive Plan
Granted (in shares)		600,000
Vesting, achievement of arithmetic average of closing stock price per share for each trading day, period			90 days
Vesting, achievement of arithmetic average of closing stock price per share for each trading day, share price, minimum (in dollars per share)			$ 20
Vesting, achievement of arithmetic average of closing stock price per share for each trading day, share price, maximum (in dollars per share)			$ 60
Vesting, immediately vest in full, change in control, shares of stock cease to trade on nationally recognized exchange, percentage (as a percent)			100%
Vesting, immediately vest in full, qualifying termination, period			12 months
Time-based Restricted Stock Units | July 2023
Stock Incentive Plan
Vesting term	5 years
Performance-based Restricted Stock Units | July 2023
Stock Incentive Plan
Vesting percentage (as a percent)			10%
Vesting, achievement of arithmetic average of closing stock price per share for each trading day, vesting percentage, minimum (as a percent)			20%
Performance-based Restricted Stock Units | July 2023 | Share-Based Payment Arrangement, Tranche One
Stock Incentive Plan
Vesting term		4 years
Performance-based Restricted Stock Units | July 2023 | Share-Based Payment Arrangement, Tranche Two
Stock Incentive Plan
Vesting term	5 years

Stock Incentive Plan - Stock-Ba

Stock Incentive Plan - Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Mar. 31, 2024	Mar. 31, 2024
Restricted Stock Units (RSUs)
Stock Incentive Plan
Stock-based compensation expense	$ 135	$ 296

Stock Incentive Plan - Cost Not

Stock Incentive Plan - Cost Not yet Recognized (Details) - Restricted Stock Units (RSUs) $ in Millions	9 Months Ended
	Mar. 31, 2024 USD ($)
Stock Incentive Plan
Cost not yet recognized, amount	$ 2,967
Cost not yet recognized, period for recognition	4 years 1 month 6 days

Commitments and Contingencies -

Commitments and Contingencies - Environmental (Details) $ in Thousands	9 Months Ended
	Mar. 31, 2024 USD ($) item	Jun. 30, 2023 USD ($)
Environmental
Number of potentially responsible parties | item	140
Accrual for environmental loss contingencies | $	$ 4,270	$ 8,505
Environmental Loss Contingency, Statement of Financial Position	Other liabilities, Accrued expenses and other current liabilities	Other liabilities, Accrued expenses and other current liabilities

Derivatives - General Informati

Derivatives - General Information (Details) - Cash Flow Hedging - USD ($) $ in Thousands	1 Months Ended
	Jul. 31, 2022	Mar. 31, 2024
Interest Rate Swap
Derivatives
Derivative, notional amount		$ 300,000
Interest Rate Swap, July 2022
Derivatives
Derivative, notional amount	$ 300,000
Derivative, fixed interest rate (as a percent)	0.61%
Derivative, maturity date	Jun. 30, 2025

Derivatives - Balance Sheet Loc

Derivatives - Balance Sheet Location (Details) - Cash Flow Hedging - USD ($) $ in Thousands	Mar. 31, 2024	Jun. 30, 2023
Foreign Exchange Option
Other assets
Total Fair Value	$ 467	$ 333
Foreign Exchange Option | Other Current Assets
Other assets
Other assets	467	333
Interest Rate Swap
Other assets
Total Fair Value	15,813	24,256
Interest Rate Swap | Other Current Assets
Other assets
Other assets	13,080	14,031
Interest Rate Swap | Other Noncurrent Assets
Other assets
Other assets	$ 2,733	$ 10,225

Derivatives - Notional Amounts

Derivatives - Notional Amounts (Details) - Mar. 31, 2024 - Cash Flow Hedging R$ in Thousands, $ in Thousands	USD ($)	BRL (R$)
Foreign Exchange Option | Brazil, Brazil Real | Long
Derivatives
Derivative, notional amount | R$		R$ 18000
Foreign Exchange Option | Brazil, Brazil Real | Short
Derivatives
Derivative, notional amount | R$		R$ 18000
Foreign Exchange Option | Israel, New Shekels | Long
Derivatives
Derivative, notional amount	$ 10,872
Foreign Exchange Option | Israel, New Shekels | Short
Derivatives
Derivative, notional amount	10,872
Interest Rate Swap
Derivatives
Derivative, notional amount	$ 300,000

Derivatives - Effects of Deriva

Derivatives - Effects of Derivatives (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Derivatives
Consolidated statement of operations - total cost of goods sold	$ 183,623	$ 170,133	$ 518,573	$ 501,269
Consolidated statement of operations - total selling, general and administrative expenses	59,676	56,987	191,043	173,490
Interest expense, net	4,575	3,871	13,798	10,822
Derivatives
(Income) expense recorded in comprehensive income	1,793	3,765	8,407	(1,804)
Foreign Exchange Option
Derivatives
(Income) expense recorded in comprehensive income	875	(83)	(35)	67
Foreign Exchange Option | Cash Flow Hedging
Derivatives
(Income) expense recorded in consolidated statements of operations	$ (183)	$ 368	$ (754)	$ 1,161
Derivative, Gain (Loss), Statement of Income or Comprehensive Income	Consolidated statement of operations - total cost of goods sold, Consolidated statement of operations - total selling, general and administrative expenses	Consolidated statement of operations - total cost of goods sold, Consolidated statement of operations - total selling, general and administrative expenses	Consolidated statement of operations - total cost of goods sold, Consolidated statement of operations - total selling, general and administrative expenses	Consolidated statement of operations - total cost of goods sold, Consolidated statement of operations - total selling, general and administrative expenses
Interest Rate Swap
Derivatives
(Income) expense recorded in comprehensive income	$ 918	$ 3,848	$ 8,442	$ (1,871)
Interest Rate Swap | Cash Flow Hedging
Derivatives
(Income) expense recorded in consolidated statements of operations	$ (3,646)	$ (2,994)	$ (10,859)	$ (6,502)
Derivative, Gain (Loss), Statement of Income or Comprehensive Income	Interest expense, net	Interest expense, net	Interest expense, net	Interest expense, net

Derivatives - Additional Inform

Derivatives - Additional Information (Details) $ in Thousands	Mar. 31, 2024 USD ($)
Foreign Exchange Option | Cash Flow Hedging
Derivatives
Realized gains (losses) related to matured contracts recorded as a component of inventory	$ 1,426

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value of Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Jun. 30, 2023
Fair Value of Assets
Short-term investments	$ 48,523	$ 40,000
Level 1
Fair Value of Assets
Short-term investments	48,523	40,000
Level 1 | Foreign Exchange Option
Fair Value of Assets
Foreign currency derivatives and interest rate swap	0	0
Level 1 | Interest Rate Swap
Fair Value of Assets
Foreign currency derivatives and interest rate swap	0	0
Level 2
Fair Value of Assets
Short-term investments	0	0
Level 2 | Foreign Exchange Option
Fair Value of Assets
Foreign currency derivatives and interest rate swap	467	333
Level 2 | Interest Rate Swap
Fair Value of Assets
Foreign currency derivatives and interest rate swap	15,813	24,256
Level 3
Fair Value of Assets
Short-term investments	0	0
Level 3 | Foreign Exchange Option
Fair Value of Assets
Foreign currency derivatives and interest rate swap	0	0
Level 3 | Interest Rate Swap
Fair Value of Assets
Foreign currency derivatives and interest rate swap	$ 0	$ 0

Fair Value Measurements - Asset

Fair Value Measurements - Assets Measured on Recurring Basis, Unobservable Inputs (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Mar. 31, 2024	Jun. 30, 2023
Changes in the fair value of the Level 3 assets
Transfers between levels, assets	$ 0	$ 0

Fair Value Measurements - Liabi

Fair Value Measurements - Liabilities Measured on Recurring Basis, Unobservable Inputs (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Mar. 31, 2024	Jun. 30, 2023
Changes in the fair value of the Level 3 liabilities
Transfers between levels, liabilities	$ 0	$ 0

Business Segments - General Inf

Business Segments - General Information (Details) - segment	3 Months Ended		9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Business Segments
Number of reportable segments	3	3	3	3

Business Segments - Net Sales (

Business Segments - Net Sales (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Net sales
Net sales	$ 263,223	$ 245,673	$ 744,515	$ 722,840
Animal Health
Net sales
Net sales	181,333	164,434	514,967	483,096
Mineral Nutrition
Net sales
Net sales	64,228	62,922	181,601	184,212
Performance Products
Net sales
Net sales	$ 17,662	$ 18,317	$ 47,947	$ 55,532

Business Segments - Depreciatio

Business Segments - Depreciation and Amortization (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Depreciation and amortization
Depreciation and amortization	$ 9,196	$ 8,489	$ 26,977	$ 25,438
Operating Segments
Depreciation and amortization
Depreciation and amortization	8,728	8,012	25,590	24,066
Operating Segments | Animal Health
Depreciation and amortization
Depreciation and amortization	7,695	6,888	22,392	20,733
Operating Segments | Mineral Nutrition
Depreciation and amortization
Depreciation and amortization	601	671	1,907	1,985
Operating Segments | Performance Products
Depreciation and amortization
Depreciation and amortization	$ 432	$ 453	$ 1,291	$ 1,348

Business Segments - Adjusted EB

Business Segments - Adjusted EBITDA (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Adjusted EBITDA
Adjusted EBITDA	$ 43,560	$ 40,489	$ 119,967	$ 118,864
Operating Segments
Adjusted EBITDA
Adjusted EBITDA	43,560	40,489	119,967	118,864
Operating Segments | Animal Health
Adjusted EBITDA
Adjusted EBITDA	36,524	34,217	104,317	98,240
Operating Segments | Mineral Nutrition
Adjusted EBITDA
Adjusted EBITDA	4,665	3,859	11,053	13,555
Operating Segments | Performance Products
Adjusted EBITDA
Adjusted EBITDA	$ 2,371	$ 2,413	$ 4,597	$ 7,069

Business Segments - Reconciliat

Business Segments - Reconciliation of Income before Income Taxes to Adjusted EBITDA (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Reconciliation of income before income taxes to Adjusted EBITDA
Income before income taxes	$ 12,922	$ 15,104	$ 4,508	$ 32,630
Interest expense, net	4,575	3,871	13,798	10,822
Depreciation and amortization	9,196	8,489	26,977	25,438
Corporate costs	13,856	13,122	42,160	38,451
Acquisition-related costs of goods sold	211		521
Acquisition-related other	512		512
Pension settlement cost			10,674
Brazil employment taxes			4,202
Insurance proceeds	(274)		(274)
Stock-based compensation			296
Foreign currency losses (gains), net	2,427	(422)	16,593	4,629
Adjusted EBITDA - Total segments	43,560	40,489	119,967	118,864
Operating Segments
Reconciliation of income before income taxes to Adjusted EBITDA
Depreciation and amortization	8,728	8,012	25,590	24,066
Stock-based compensation	135		296
Environmental remediation costs		325		6,894
Adjusted EBITDA - Total segments	43,560	40,489	119,967	118,864
Operating Segments | Animal Health
Reconciliation of income before income taxes to Adjusted EBITDA
Depreciation and amortization	7,695	6,888	22,392	20,733
Adjusted EBITDA - Total segments	36,524	34,217	104,317	98,240
Operating Segments | Mineral Nutrition
Reconciliation of income before income taxes to Adjusted EBITDA
Depreciation and amortization	601	671	1,907	1,985
Adjusted EBITDA - Total segments	4,665	3,859	11,053	13,555
Operating Segments | Performance Products
Reconciliation of income before income taxes to Adjusted EBITDA
Depreciation and amortization	432	453	1,291	1,348
Adjusted EBITDA - Total segments	2,371	2,413	4,597	7,069
Corporate
Reconciliation of income before income taxes to Adjusted EBITDA
Depreciation and amortization	$ 468	$ 477	$ 1,387	$ 1,372

Business Segments - Identifiabl

Business Segments - Identifiable Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Jun. 30, 2023
Assets
Assets	$ 979,035	$ 971,397
Operating Segments
Assets
Assets	820,373	824,014
Operating Segments | Animal Health
Assets
Assets	701,252	698,522
Operating Segments | Mineral Nutrition
Assets
Assets	69,846	75,814
Operating Segments | Performance Products
Assets
Assets	49,275	49,678
Corporate
Assets
Assets	$ 158,662	$ 147,383

Subsequent Event (Details)

Subsequent Event (Details) - Subsequent Event $ in Thousands	1 Months Ended
	Apr. 30, 2024 USD ($)
Secured Debt | Senior Secured Incremental First Lien Term Loan Facility
Subsequent Event
Aggregate principal amount	$ 325,000
Zoetis Inc Medicated Feed Additive Product Portfolio
Subsequent Event
Asset acquisition, price of acquisition, expected	$ 350,000

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ 8,405	$ 10,042	$ 1,664	$ 21,108

Insider Trading Arrangements

Insider Trading Arrangements - Jack C. Bendheim	3 Months Ended
	Mar. 31, 2024 shares
Trading Arrangements, by Individual
Material Terms of Trading Arrangement	Item 5. Other Inf On February 12, 2024, BFI Co., LLC (“BFI”) adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act for the sale of up to 528,000 shares of Class A common stock through November 15, 2024. Jack C. Bendheim, our Chairman of the Board of Directors, President and Chief Executive Officer, has sole authority to vote shares of our stock owned by BFI.
Name	Jack C. Bendheim
Title	Chairman of the Board of Directors, President and Chief Executive Officer
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	February 12, 2024
Aggregate Available	528,000
Trd Arr Expiration Date	Nov. 15, 2024